Kerry af Forselles on Muck Rack

Kerry af Forselles

As seen in: Markets Insider, Associated Press: Press Releases, KOIN-TV (Portland, OR), ADVFN, WKRG-TV (Mobile, AL), WNCN-TV (Raleigh, NC), MENAFN, WAVY-TV (Portsmouth, VA), WWLP-TV (Chicopee, MA), WPIX-TV (New York, NY) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kerry af

Contact Kerry af, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis

|
By Ali Guermazi, Philip G Conaghan, Kerry af Forselles
| UK Daily News Online
Clinical and Pharmacology Data Presented at ACR Convergence 2025 In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with osteoarthritis (OA) A significant correlation between improvements in OA symptoms and positive effects on bone structure suggests disease modification potential In newly reported pre-clinical data, there was no evidence of worsening of joint pathology with LEVI-04 treatment.
Open in Who Shared View Duplicates (142) Issue with article?

Levicept to Present Key New Data from Phase II Trial of LEVI-04, a Novel Neurotrophin-3 Inhibitor, at ACR Convergence 2025

|
By Ali Guermazi, Philip G Conaghan, Kerry af Forselles
| KSWB-TV (San Diego, CA)
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients with osteoarthritis Changes in bone marrow lesion area were significantly correlated with changes in patient-reported symptoms including pain Further presentations detail LEVI-04 mechanism of action, functional outcomes and imaging screening exclusions LEVI-04 is a first-in-class novel biologic under development as non-addictive pain treatment SANDWICH,...
Open in Who Shared View Duplicates (64) Issue with article?
See all 54 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Kerry af

Contact Kerry af, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified